NCT01580839View on ClinicalTrials.gov

EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International)

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 6, 2012

Primary Completion Date

August 22, 2018

Study Completion Date

August 22, 2018

Conditions
Stroke
Interventions
DRUG

Tissue Plasminogen Activator (Alteplase)

0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour

DRUG

Placebo

placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug

Trial Locations (1)

40447

China Medical University Hospital, Taichung

Sponsors
All Listed Sponsors
collaborator

China Medical University Hospital

OTHER

lead

Neuroscience Trials Australia

OTHER

NCT01580839 - EXTEND (International): Extending the Time for Thrombolysis in Emergency Neurological Deficits (International) | Biotech Hunter | Biotech Hunter